Compounded GLP-1 Telehealth Shutdown Tracker: Which Providers Still Advertise Semaglutide or Tirzepatide in 2026?

The short answer: the easy national shortcut for copycat compounded semaglutide and tirzepatide is mostly closing, but it has not disappeared. Big telehealth brands are splitting into two groups. Hims, Noom, Ro, and WeightWatchers now emphasize FDA-approved or direct-pay brand paths. Henry Meds and Mochi still publicly advertise compounded semaglutide or tirzepatide programs, based on pages reviewed June 19, 2026.

FDA is the reason this changed. FDA says the tirzepatide injection shortage was resolved on December 19, 2024, and the semaglutide injection shortage was resolved on February 21, 2025. FDA also says tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.

That does not mean every individualized compounded prescription is automatically illegal. FDA's 503A framework still turns on patient-specific prescriptions and documented clinical differences. It does mean mass-market copycat GLP-1 programs are a much harder claim to defend than they were during the shortage era.

Use this tracker as a buyer checklist, not as a pharmacy source list. PeptidePub does not recommend gray-market peptides, research vials, or vendor sourcing.

June 29 Access and Enforcement Update

The June 29 read is mixed. The confirmed public signals are mostly access and marketing changes, not a clean nationwide shutdown. Hims and Novo Nordisk resolved their early-2026 dispute with a brand-drug agreement. Hims said it would no longer advertise compounded GLP-1 offerings on its platform or in marketing, while Novo said Hims could still support compounded use only when a provider finds it clinically necessary.

Noom's current public Noom Med page does not present a simple compounded semaglutide or tirzepatide cash menu. It says medication costs vary by treatment plan, lists brand-name medications such as Ozempic and Zepbound with out-of-pocket costs depending on insurance, and separately advertises a Microdose GLP-1 Rx program starting at $99. Treat that as a page-removal or public-positioning signal, not proof that every checkout path is brand-only.

Empower remains an important pharmacy-access signal. Its public GLP-1 page says it can provide compounded semaglutide with cyanocobalamin and tirzepatide with niacinamide from a 503A PCAB-accredited compounding pharmacy. Its New Jersey page says it supports patients and businesses in New Jersey with patient-specific and office-use certifications. That means buyers should verify the actual dispensing pharmacy, state license, formulation, and prescription basis instead of assuming that New Jersey access ended everywhere.

Service-group, clinic, or discount posts can point to continued demand, but they are weaker evidence than provider pages, pharmacy pages, regulator pages, lawsuits, or checkout terms. If a group discount claims unusually cheap compounded GLP-1 access, verify the legal provider, dispensing pharmacy, concentration, dose units, and recurring fees before treating the post as a real offer.

FDA's safety warning is separate from any one provider. FDA says unapproved GLP-1 drugs are not reviewed for safety, effectiveness, or quality before marketing. FDA has flagged dosing errors, salt forms, illegal online sales, fraudulent labels, fake pharmacy attribution, and adverse-event reports tied to compounded semaglutide and compounded tirzepatide. That is a product-quality and buyer-safety concern, not proof that every individualized compounded prescription is unlawful.

July 3 Legal Pressure Update: IP, Ads, and Mass-Market Copycat Claims

The current pressure is no longer just a general safety warning. It is now a combined FDA, manufacturer, advertising, and intellectual-property pressure campaign against mass-marketed GLP-1 copycats.

FDA's April 1, 2026 compounding update draws the clearest regulatory line. A 503A pharmacy may compound for an individual patient prescription, but FDA says a product can be treated as an essentially copied commercially available drug when it uses the same API in the same, similar, or easily substitutable strength and the approved drug can be used by the same route. FDA also says a prescriber-documented significant difference for an identified individual patient is different from routine national copycat marketing.

The Hims dispute shows why this matters for telehealth checkout pages. Novo Nordisk sued Hims & Hers on February 9, 2026, alleging infringement of US Patent No. 8,129,343 and accusing Hims of mass-marketing unapproved compounded semaglutide products. Legal commentary from Brian J. Malkin and Elizabeth A. Siemer in Pharmacy Times described the suit alongside FDA's February 2026 warning that unresolved violations may lead to legal action without further notice, including seizure and injunction. Novo later dismissed the case without prejudice after a March 2026 branded-product agreement, but the pattern is the point: legal pressure can change advertising, checkout flows, and partnership terms quickly.

The buyer read is practical. A legitimate individualized 503A prescription should be tied to your medical need, your prescriber's documented rationale, and a real state-licensed pharmacy. A mass-market claim that a product is generic semaglutide, generic tirzepatide, the same active ingredient as Wegovy or Zepbound, or clinically equivalent because STEP 1 or SURMOUNT-1 exists is a different risk profile. Those trials studied FDA-approved products, not every compounded vial, tablet, or altered formulation.

Before paying, add three legal-pressure checks to the normal pharmacy checklist:

1. Ask whether the provider is selling an FDA-approved drug, a 503A patient-specific compounded prescription, or a 503B outsourcing-facility product.

1. Ask what individualized clinical difference is documented if the offer uses the same API and route as an available FDA-approved product.

1. Avoid offers that frame compounded semaglutide or tirzepatide as generic Wegovy, generic Ozempic, generic Zepbound, or a guaranteed equivalent to a brand trial result.

This is not legal advice and it is not a sourcing guide. It is a signal that regulatory status, advertising language, and pharmacy identity now matter as much as headline price.

Legal-pressure sources: FDA's April 1, 2026 compounding policy update, FDA's unapproved GLP-1 safety page, Novo Nordisk's February 9, 2026 Hims lawsuit announcement, and Pharmacy Times' March 26, 2026 analysis by Brian J. Malkin and Elizabeth A. Siemer.

Current Provider Tracker

This table can change quickly. Treat it as a snapshot from pages reviewed on June 19 and June 29, 2026. If a checkout screen conflicts with the public page, screenshot the terms and ask the provider to clarify the exact medication, pharmacy, and recurring cost before paying.

What FDA Actually Says Now

FDA's current position is narrower than many ads make it sound.

For 503A pharmacies, FDA says a compounded drug must be for an individual patient prescription, and the compounder cannot regularly or in inordinate amounts compound drugs that are essentially copies of commercially available products. FDA says a prescriber can document a significant difference for an identified individual patient, but that is not the same as a national copycat program.

For 503B outsourcing facilities, FDA says facilities are restricted from compounding with bulk drug substances unless the substance is on the 503B bulks list or the drug is on FDA's shortage list at the time of compounding, distribution, and dispensing. FDA's April 1, 2026 update says semaglutide and tirzepatide are not currently on either list.

FDA's enforcement-discretion deadlines tied to the GLP-1 shortages have also passed. Tirzepatide's 503A window ended in February 2025 and 503B window ended in March 2025. Semaglutide's 503A window ended in April 2025, with the 503B window ending in May 2025 after litigation did not block FDA's approach.

The April 30, 2026 proposal matters because it would further narrow 503B bulk compounding. FDA said it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk substances. A proposal is not the same thing as a final rule, but it is a strong direction-of-travel signal.

Why Telehealth Companies Are Moving

The old business model was simple: brand-name GLP-1s were expensive or hard to find, compounded alternatives were cheaper, and telehealth companies could advertise access at a fraction of list price. The shortage era made that easier.

The post-shortage era is different. FDA-approved manufacturers now have more direct-pay routes, some telehealth platforms have negotiated brand access, and FDA has clarified that shortage-based copycat compounding cannot continue as the default national access path.

Hims is the clearest example. In March 2026, Hims & Hers announced a Novo Nordisk agreement to bring Ozempic and Wegovy products to its platform and described the move as a strategic shift in its US weight-loss business. Hims said it would no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Its current public weight-loss page now lists brand routes such as Wegovy pill, Wegovy pen, Zepbound vial, Zepbound KwikPen, Foundayo pill, Ozempic, Mounjaro, and Zepbound.

Noom's public Noom Med page now lists a mix of brand GLP-1s, oral options, generic liraglutide, metformin, and lifestyle support. Its current page says medication costs vary by treatment plan and separately advertises a Microdose GLP-1 Rx program starting at $99. Ro's pricing page emphasizes membership, GLP-1 access if appropriate, insurance coverage help, and medication cost based on treatment and coverage. WeightWatchers' public medication page highlights FDA-approved obesity drugs and clinical care.

Henry Meds and Mochi are still different. Henry's legal programs page continues to list compounded semaglutide and oral tirzepatide programs. Mochi's FAQ continues to list compounded semaglutide and tirzepatide prices. Empower's public GLP-1 page continues to advertise compounded GLP-1 solutions for patients and clinics through a 503A pharmacy. None of that proves the programs are unlawful. It does mean buyers need to ask harder regulatory and pharmacy questions before treating a low price as the whole story.

The Price Gap Is Still Real

The reason compounded GLP-1s remain attractive is obvious. The price gap can be hundreds or more than a thousand dollars per month.

Public pages reviewed in June 2026 show Hims listing brand or direct-pay medication prices such as Wegovy pill from $149/mo, Wegovy pen from $199/mo, Zepbound vial or KwikPen from $299/mo, and Foundayo pill from $149/mo, with membership billed separately. Noom lists its Microdose GLP-1 Rx program as starting at $99, while saying brand-name medication out-of-pocket costs depend on insurance coverage. Henry lists compounded semaglutide injection at $297/mo and oral semaglutide at $249/mo. Mochi lists compounded semaglutide at $99/mo and compounded tirzepatide at $199/mo, plus membership.

Those numbers are not apples to apples. Brand-name products are FDA-approved finished drugs with labeled manufacturing, pharmacology, and clinical-trial packages. Compounded products are not FDA-approved finished drugs and are not reviewed by FDA for safety, effectiveness, or quality before marketing.

Trial data also belongs mostly to FDA-approved products, not compounded copycats. In STEP 1, Wilding and colleagues reported in the New England Journal of Medicine that semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo. In SURMOUNT-1, Jastreboff and colleagues reported tirzepatide weight reductions of 16.0%, 21.4%, and 22.5% at 72 weeks for 5 mg, 10 mg, and 15 mg, versus 2.4% with placebo.

Use those results as medication-class context, not as proof that every compounded vial, oral tablet, or altered formulation will perform the same.

Safety Signals Buyers Should Not Ignore

FDA's unapproved GLP-1 warning page is not subtle. FDA says unapproved GLP-1 drugs have not gone through FDA review for safety, effectiveness, or quality. FDA has flagged fraudulent compounded semaglutide and tirzepatide labels, pharmacies named on labels that do not exist, products falsely tied to licensed pharmacies, dosing errors, salt forms, and illegal online sales.

FDA adverse-event reporting is also meaningful, even with underreporting. As of July 31, 2025, FDA had received 605 adverse-event reports associated with compounded semaglutide and 545 associated with compounded tirzepatide. FDA says those reports are likely undercounted because state-licensed pharmacies that are not outsourcing facilities do not have the same mandatory adverse-event reporting requirement.

This is why a low cash price should trigger more verification, not less. Ask for the dispensing pharmacy name, state license, whether the product is 503A or 503B, whether the prescription is patient-specific, whether any ingredient was added, exact concentration, dose in milligrams and units, storage requirements, shipping temperature process, and who handles side effects.

If a provider will not identify the pharmacy or gives vague answers about the medication, do not buy.

Buyer Decision Framework

Choose a brand or direct-pay route first if you can afford it, qualify clinically, or have insurance help. That usually means Wegovy, Zepbound, Ozempic or Mounjaro when appropriate, Foundayo, Wegovy pill, NovoCare, LillyDirect, or a telehealth platform now routing through approved products.

Consider a telehealth compounded route only if the provider can document why a compounded product is clinically needed for you as an individual patient, identify the pharmacy, explain the exact formulation, and give clear dosing instructions in both milligrams and syringe units. Do not accept broad claims that compounding is automatically equivalent because the active ingredient sounds familiar.

Avoid gray-market sellers, research-use vials, peptide marketplaces, and social-media sourcing. These are not substitutes for a licensed clinician and pharmacy.

If you are shopping by cost, compare cheapest semaglutide online, compounded tirzepatide cost, GLP-1 without insurance, and best online weight-loss program. For the regulatory foundation, read compounded versus brand GLP-1s.

Verification Checklist Before You Pay

1. Confirm the exact medication name, active ingredient, route, and dosage form.

1. Ask whether the product is FDA-approved or compounded. Do not let marketing terms blur that line.

1. Ask for the dispensing pharmacy's legal name, state license, and whether it is a 503A pharmacy or 503B outsourcing facility.

1. Ask why a compounded product is clinically necessary for you as an individual patient.

1. Ask for dose instructions in milligrams and syringe units, plus a sample label if allowed.

1. Confirm first-month price, refill price, membership fee, shipping fee, dose-escalation fee, cancellation deadline, and refund policy.

1. Check whether the provider offers brand alternatives, insurance support, NovoCare, LillyDirect, or Medicare Bridge routing when eligible.

1. If the offer came from a service group, discount post, or clinic promotion, verify the provider's legal name, the dispensing pharmacy, and the same recurring price in the checkout terms.

1. Save screenshots of public pricing and checkout terms before submitting payment.

FAQ

Are compounded semaglutide and tirzepatide banned in 2026? Not as a blanket statement. FDA's current position is that shortage-based mass copycat compounding is no longer the easy path it was during the shortage era. Patient-specific 503A compounding can still exist when legal conditions are met, including a documented significant difference for an identified patient when relevant.

Which telehealth providers stopped advertising compounded GLP-1s? Based on pages reviewed June 19 and June 29, 2026, Hims, Noom, Ro, and WeightWatchers now emphasize FDA-approved, brand, insurance, or direct-pay medication routes rather than a public compounded semaglutide or tirzepatide price menu. Noom's current Microdose GLP-1 Rx language still deserves checkout-level verification.

Which providers still advertise compounded GLP-1s? Henry Meds and Mochi still publicly advertise compounded GLP-1 programs on pages reviewed June 19, 2026. Henry lists compounded semaglutide and oral tirzepatide programs. Mochi lists compounded semaglutide and compounded tirzepatide medication pricing. Empower also publicly advertises compounded GLP-1 solutions for patients and clinics through a 503A pharmacy.

Is the cheapest compounded GLP-1 option the best option? No. Low price is useful only after you verify clinician oversight, pharmacy identity, state licensing, formulation, dosing clarity, shipping controls, and legal rationale. FDA-approved products have a stronger evidence and quality-control package.

Can I use STEP 1 or SURMOUNT-1 results to judge compounded products? Only as background. STEP 1 studied semaglutide 2.4 mg injection. SURMOUNT-1 studied tirzepatide injection. Those trials do not prove that every compounded injection, altered formulation, oral tablet, or nonstandard product has the same safety or effectiveness.

Sources

FDA: GLP-1 compounding policy update, 503B bulks-list proposal, and unapproved GLP-1 safety concerns.

Provider and pharmacy pages reviewed June 19 and June 29, 2026: Hims weight loss, Hims strategic shift announcement, Noom Med, Ro weight-loss pricing, WeightWatchers medication clinic, Henry Meds programs, Mochi FAQ, Empower GLP-1 agonists, and Empower New Jersey coverage.

Clinical trials: Wilding JPH et al., New England Journal of Medicine, 2021, STEP 1 semaglutide 2.4 mg trial. Jastreboff AM et al., New England Journal of Medicine, 2022, SURMOUNT-1 tirzepatide trial.

Bottom Line

The telehealth GLP-1 market has not fully shut down, but it has shifted. The safest read in 2026 is this: large platforms are moving toward FDA-approved, brand, insurance, or direct-pay paths, while some lower-cost clinics and pharmacy-linked programs still advertise compounded access under narrower regulatory conditions.

Start with approved routes when possible. If you compare compounded options, verify the pharmacy and prescription rationale before you compare price.